David R. Spriggs: Publications

C. Aghajanian, D.S. Dizon, P. Sabbatini, J.J. Raizer, J. Dupont, and D.R. Spriggs. A Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. J Clin Oncol. 2005 Sep 1;23(25):5943-9.

Aliza L. Leiser, Guangli Yang, Huasong Tian, Gregory Springett, Magdalena Dabrowska, Xiu Jun Yan, Nestor Rosales, William Bornmann, David R. Spriggs. Novel Tetrafluorodinated Phthalimide Analogues with 'are' Dependent TNF-ALPHA Regulatory Activity. [In Press]

Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004 Aug 15;22(16):3330-9.

Springett GM, Kawasaki H, Spriggs DR. Non-kinase second-messenger signaling: new pathways with new promise. Bioessays. 2004 Jul;26(7):730-8. Review.

Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003 Oct;91(1):123-9.

Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998 Mar 15;58(6):1120-3.

Wang E, Ma WJ, Aghajanian C, Spriggs DR. Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3'-untranslated region of tumor necrosis factor-alpha messenger RNA. Cancer Res. 1997 Dec 1;57(23):5426-33.